Deep Dive: Oncology and ASCO 2019 Archives -

The promise and pitfalls of molecular testing in oncology

mike.hammerton@pharmaphorum.com cancer, Deep Dive: Oncology and ASCO 2019, Dr Chris Gaj, erlotinib, Genentech, OSI, Research Partnership, Roche 0 Comment

Great strides have been made in the diagnosis and treatment of cancer. However, a variety of challenges remain

The promise and pitfalls of molecular testing in oncology

https://pharmaphorum.com/deep-dive/research-partnership-molecular-testing-cancer/

Deep Dive/ Oncology/ Views & Analysis

Smarter thinking about pharmaceutical marketing

mike.hammerton@pharmaphorum.com Deep Dive: Oncology and ASCO 2019, marketing, Multichannel, patient, Robb DeFilippis, Tag 0 Comment

Robb DeFilippis, from end-to-end global creative production and sourcing partner Tag, discusses how a more effective multichannel pharma

Smarter thinking about pharmaceutical marketing

https://pharmaphorum.com/deep-dive/tag-pharmaceutical-marketing-production/

Deep Dive/ Oncology/ Views & Analysis/ Views and analysis

Getting patients round the virtual table

mike.hammerton@pharmaphorum.com Deep Dive: Oncology and ASCO 2019, engagement, impetus, patient-centric 0 Comment

If pharma wants to be truly patient-centric, it needs to be talking to patients. This may seem obvious,

Getting patients round the virtual table

https://pharmaphorum.com/views-analysis-oncology/impetus-digital-patient-centric-engagement/

Deep Dive/ Oncology/ Views & Analysis/ Views and analysis

Revealing the true value of new cancer drugs to payers

mike.hammerton@pharmaphorum.com Ben van Hout, CAR T, Deep Dive: Oncology and ASCO 2019, Marc Botteman, pharmerit international 0 Comment

Marc Botteman and Ben van Hout from Pharmerit International discuss how to navigate the value challenges of new

Revealing the true value of new cancer drugs to payers

https://pharmaphorum.com/deep-dive/pharmerit-cancer-drug-value-payers/

Adapting for the future of clinicial trials

Deep Dive/ Oncology/ Views & Analysis/ Views and analysis

Adapting for the future of oncology trials

mike.hammerton@pharmaphorum.com Cytel, Deep Dive: Oncology and ASCO 2019, Oncology, R&D 0 Comment

Advanced analytical solutions provider Cytel is at the forefront of rapid changes in oncology R&D. We spoke with

Adapting for the future of oncology trials

https://pharmaphorum.com/views-analysis-oncology/cytel-future-adaptive-trials-cancer/

Deep Dive/ Oncology/ Views & Analysis/ Views and analysis

Moving from autologous to allogeneic ACT paradigms

mike.hammerton@pharmaphorum.com ACT, Acute Lymphocytic Leukaemia, Adoptive Cellular Transfer, CAR T, Deep Dive: Oncology and ASCO 2019, Gilead, ICON, Novartis 0 Comment

We have come so far in a relatively short time with Adoptive Cellular Transfer (ACT). The two marketed

Moving from autologous to allogeneic ACT paradigms

https://pharmaphorum.com/deep-dive/icon-allogeneic-adoptive-cellular-transfer/

Deep Dive/ Oncology/ Views & Analysis

Did cancer clinical trials stay on track at ASCO 2019?

mike.hammerton@pharmaphorum.com asco, cancer, Deep Dive: Oncology and ASCO 2019, kantar 0 Comment

Chicago is recovering after 40,000 oncologists and cancer experts descended on the city for this year’s ASCO conference.

Did cancer clinical trials stay on track at ASCO 2019?

https://pharmaphorum.com/deep-dive/kantar-cancer-clinical-trials/

Deep Dive/ Oncology/ Views & Analysis/ Views and analysis

Why pharma needs honest patient dialogue

mike.hammerton@pharmaphorum.com Astellas, Deep Dive: Oncology and ASCO 2019, Dr Paul Tunnah, Percival Barretto-Ko 0 Comment

Astellas Pharma US president Percival Barretto-Ko talks with Dr Paul Tunnah about drug pricing, collaboration and improving the

Why pharma needs honest patient dialogue

https://pharmaphorum.com/deep-dive/astellas-pharma-percival-barretto-ko/

Trending

Deep Dive: Oncology and ASCO 2019

Login